Fig. 7From: Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model Cost-effectiveness planes of CUA of alternative regimens in the first-line treatment of HR + / HER2- MBCBack to article page